281 related articles for article (PubMed ID: 26003048)
1. CCR9-mediated signaling through β-catenin and identification of a novel CCR9 antagonist.
Lee S; Heinrich EL; Li L; Lu J; Choi AH; Levy RA; Wagner JE; Yip ML; Vaidehi N; Kim J
Mol Oncol; 2015 Oct; 9(8):1599-611. PubMed ID: 26003048
[TBL] [Abstract][Full Text] [Related]
2. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion.
Johnson-Holiday C; Singh R; Johnson EL; Grizzle WE; Lillard JW; Singh S
World J Surg Oncol; 2011 May; 9():46. PubMed ID: 21539750
[TBL] [Abstract][Full Text] [Related]
3. CCR9 in cancer: oncogenic role and therapeutic targeting.
Tu Z; Xiao R; Xiong J; Tembo KM; Deng X; Xiong M; Liu P; Wang M; Zhang Q
J Hematol Oncol; 2016 Feb; 9():10. PubMed ID: 26879872
[TBL] [Abstract][Full Text] [Related]
4. CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide.
Sharma PK; Singh R; Novakovic KR; Eaton JW; Grizzle WE; Singh S
Int J Cancer; 2010 Nov; 127(9):2020-30. PubMed ID: 20127861
[TBL] [Abstract][Full Text] [Related]
5. CCR9-CCL25 interaction suppresses apoptosis of lung cancer cells by activating the PI3K/Akt pathway.
Li B; Wang Z; Zhong Y; Lan J; Li X; Lin H
Med Oncol; 2015 Mar; 32(3):66. PubMed ID: 25691296
[TBL] [Abstract][Full Text] [Related]
6. CCL25/CCR9 interaction promotes the malignant behavior of salivary adenoid cystic carcinoma
Chai S; Wen Z; Zhang R; Bai Y; Liu J; Li J; Kongling W; Chen W; Wang F; Gao L
PeerJ; 2022; 10():e13844. PubMed ID: 36003306
[TBL] [Abstract][Full Text] [Related]
7. The role of the CCL25-CCR9 axis in beta-cell function: potential for therapeutic intervention in type 2 diabetes.
Atanes P; Lee V; Huang GC; Persaud SJ
Metabolism; 2020 Dec; 113():154394. PubMed ID: 33058852
[TBL] [Abstract][Full Text] [Related]
8. CCL25 chemokine-guided stem cell attraction: an assessment of possible benefits and risks.
Spinnen J; Ringe J; Sittinger M
Regen Med; 2018 Oct; 13(7):833-844. PubMed ID: 30284497
[TBL] [Abstract][Full Text] [Related]
9. A novel ent-kaurane diterpenoid executes antitumor function in colorectal cancer cells by inhibiting Wnt/β-catenin signaling.
Ye Q; Yao G; Zhang M; Guo G; Hu Y; Jiang J; Cheng L; Shi J; Li H; Zhang Y; Liu H
Carcinogenesis; 2015 Mar; 36(3):318-26. PubMed ID: 25600769
[TBL] [Abstract][Full Text] [Related]
10. CCL25/CCR9 Signal Promotes Migration and Invasion in Hepatocellular and Breast Cancer Cell Lines.
Zhang Z; Sun T; Chen Y; Gong S; Sun X; Zou F; Peng R
DNA Cell Biol; 2016 Jul; 35(7):348-57. PubMed ID: 27008282
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3.
Pramanik KC; Fofaria NM; Gupta P; Ranjan A; Kim SH; Srivastava SK
Oncotarget; 2015 May; 6(13):11561-74. PubMed ID: 25869100
[TBL] [Abstract][Full Text] [Related]
12. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.
Johnson EL; Singh R; Singh S; Johnson-Holiday CM; Grizzle WE; Partridge EE; Lillard JW
World J Surg Oncol; 2010 Jul; 8():62. PubMed ID: 20649989
[TBL] [Abstract][Full Text] [Related]
13. CCR9 and CCL25: A review of their roles in tumor promotion.
Xu B; Deng C; Wu X; Ji T; Zhao L; Han Y; Yang W; Qi Y; Wang Z; Yang Z; Yang Y
J Cell Physiol; 2020 Dec; 235(12):9121-9132. PubMed ID: 32401349
[TBL] [Abstract][Full Text] [Related]
14. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion.
Johnson-Holiday C; Singh R; Johnson E; Singh S; Stockard CR; Grizzle WE; Lillard JW
Int J Oncol; 2011 May; 38(5):1279-85. PubMed ID: 21344163
[TBL] [Abstract][Full Text] [Related]
15. Rab11a sustains GSK3β/Wnt/β-catenin signaling to enhance cancer progression in pancreatic cancer.
Yu L; Li X; Li H; Chen H; Liu H
Tumour Biol; 2016 Oct; 37(10):13821-13829. PubMed ID: 27481517
[TBL] [Abstract][Full Text] [Related]
16. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
Zhang C; Zhang Z; Zhang S; Wang W; Hu P
Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
[TBL] [Abstract][Full Text] [Related]
17. Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis.
Chen HJ; Edwards R; Tucci S; Bu P; Milsom J; Lee S; Edelmann W; Gümüs ZH; Shen X; Lipkin S
J Clin Invest; 2012 Sep; 122(9):3184-96. PubMed ID: 22863617
[TBL] [Abstract][Full Text] [Related]
18. ZNF281 Promotes Growth and Invasion of Pancreatic Cancer Cells by Activating Wnt/β-Catenin Signaling.
Qian Y; Li J; Xia S
Dig Dis Sci; 2017 Aug; 62(8):2011-2020. PubMed ID: 28523575
[TBL] [Abstract][Full Text] [Related]
19. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer.
Cui J; Jiang W; Wang S; Wang L; Xie K
Curr Pharm Des; 2012; 18(17):2464-71. PubMed ID: 22372504
[TBL] [Abstract][Full Text] [Related]
20. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer.
Singh R; Stockard CR; Grizzle WE; Lillard JW; Singh S
Int J Oncol; 2011 Aug; 39(2):373-81. PubMed ID: 21637913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
